CSIMarket
 


Blueprint Medicines Corporation  (BPMC)
Other Ticker:  
 
 

BPMC's Capital Expenditures Growth by Quarter and Year

Blueprint Medicines's Capital Expenditures results by quarter and year




BPMC Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 4.67 1.48 259.41 0.69
III Quarter September 6.25 3.73 1.00 0.01
II Quarter June 2.55 2.56 0.66 0.94
I Quarter March 2.58 1.15 0.17 1.53
FY   16.05 8.92 261.24 3.17



BPMC Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Blueprint Medicines Corporation reported Capital Expenditures surge of 215.74% year on year in the fourth quarter 2023, to $ 4.67 millions, this is lower than Blueprint Medicines Corporation's recent average Capital Expenditures surge of 2176.7%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Capital Expenditures growth. While Blueprint Medicines Corporation' s Capital Expenditures doubling of 215.74% ranks overall at the positon no. 452 in the fourth quarter 2023.




BPMC Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 215.74 % -99.43 % 37495.65 % -82.26 %
III Quarter September 67.56 % 273 % 9900 % -99.84 %
II Quarter June -0.39 % 287.88 % -29.79 % -56.68 %
I Quarter March 124.35 % 576.47 % -88.89 % -13.56 %
FY   79.97 % -96.59 % 8141.01 % -77.37 %

Financial Statements
Blueprint Medicines's fourth quarter 2023 Capital Expenditures $ 4.67 millions BPMC's Income Statement
Blueprint Medicines's fourth quarter 2022 Capital Expenditures $ 1.48 millions Quarterly BPMC's Income Statement
New: More BPMC's historic Capital Expenditures Growth >>


BPMC Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -25.23 % -60.32 % 25841 % 6800 %
III Quarter September 145.1 % 45.7 % 51.52 % -98.94 %
II Quarter June -1.16 % 122.61 % 288.24 % -38.56 %
I Quarter March 74.32 % -99.56 % -75.36 % -60.67 %
FY (Year on Year)   79.97 % -96.59 % 8141.01 % -77.37 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #44
Overall #452

Capital Expenditures Y/Y Growth Statistics
High Average Low
17185.01 % 2176.7 % -96.59 %
(Jun 30 2022)   (Dec 31 2022)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #44
Overall #452
Capital Expenditures Y/Y Growth Statistics
High Average Low
17185.01 % 2176.7 % -96.59 %
(Jun 30 2022)   (Dec 31 2022)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Blueprint Medicines's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
25945.18 % 1214.73 % -99.56 %
(Dec 31 2021)  


BPMC's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Blueprint Medicines Corporation disclosed fall in Capital Expenditures sequentially by -25.23% to $ 4.67 millions, from $ 6.25 millions released in the previous quarter.

This is not important issue, as Capital Expenditures always gravitate to plunge in the IV. Quarter Josefin Olofsson, an industry consultant allocated in Stockholm wrote.

Within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Blueprint Medicines's Capital Expenditures growth quarter on quarter, overall rank is 432.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #38
Overall #432
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #38
Overall #432
Capital Expenditures Q/Q Growth Statistics
High Average Low
25945.18 % 1214.73 % -99.56 %
(Dec 31 2021)  


BPMC's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Blueprint Medicines Corporation realized fall in Capital Expenditures from the previous quarter by -25.23% to $ 4.67 millions, from $ 6.25 millions released in the previous quarter.

If you analyse recent shortcoming at the IV. Quarter, you suppose to presume, that commonly IV. Quarter performance emerge sluggish relative to the preciding period, Josefin Olofsson, an industry consultant allocated in Stockholm said.

Within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Blueprint Medicines's Capital Expenditures growth quarter on quarter, overall rank is 432.


Blueprint Medicines's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 16.06 $ 12.87 $ 10.35 $ 10.35 $ 8.92
Y / Y Capital Expenditures Growth (TTM) 80.09 % -95.18 % -96.08 % -96.05 % -96.59 %
Year on Year Capital Expenditures Growth Overall Ranking # 452 # 2 # 1 # 0 # 0
Seqeuential Capital Expenditures Change (TTM) 24.8 % 24.37 % -0.02 % 16.04 % -96.66 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 452 # 188 # 420 # 498 # 0




Cumulative Capital Expenditures growth Comment
Although Blueprint Medicines's Annual Capital Expenditures growth year on year were below company's average 2176.7% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 80.09% year on year, from -95.18% in Sep 30 2023.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 2 to 452.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
17185.01 %
2176.7 %
-96.59 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 44
Overall # 452

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
17185.01 %
2176.7 %
-96.59 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 44
S&P 500 # 452
Cumulative Capital Expenditures growth Comment
Although Blueprint Medicines's Annual Capital Expenditures growth year on year were below company's average 2176.7% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 80.09% year on year, from -95.18% in Sep 30 2023.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 2 to 452.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
17185.01 %
2176.7 %
-96.59 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 44
Overall # 452

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
17185.01 %
2176.7 %
-96.59 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 44
S&P 500 # 452




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
BPMC's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for BPMC's Competitors
Capital Expenditures Growth for Blueprint Medicines's Suppliers
Capital Expenditures Growth for BPMC's Customers

You may also want to know
BPMC's Annual Growth Rates BPMC's Profitability Ratios BPMC's Asset Turnover Ratio BPMC's Dividend Growth
BPMC's Roe BPMC's Valuation Ratios BPMC's Financial Strength Ratios BPMC's Dividend Payout Ratio
BPMC's Roa BPMC's Inventory Turnover Ratio BPMC's Growth Rates BPMC's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Eyenovia inc 368.64%$ 368.638 millions
Harvard Bioscience Inc351.49%$ 351.489 millions
Urogen Pharma Ltd 330.77%$ 330.769 millions
Hims and Hers Health Inc 328.55%$ 328.550 millions
Masimo Corp295.31%$ 295.313 millions
Axonics Inc 290.15%$ 290.149 millions
Immutep Limited261.07%$ 261.067 millions
Vertex Pharmaceuticals Inc245.54%$ 245.536 millions
Prothena Corporation Public Limited Company233.84%$ 233.836 millions
Neuroone Medical Technologies Corporation222.54%$ 222.542 millions
Intuitive Surgical Inc 216.27%$ 216.267 millions
Blueprint Medicines Corporation215.53%$ 215.530 millions
Replimune Group Inc 209.73%$ 209.730 millions
Neurocrine Biosciences Inc 200.00%$ 200.000 millions
Celldex Therapeutics inc 183.40%$ 183.404 millions
Inspire Medical Systems inc 172.31%$ 172.305 millions
Olink Holding Ab publ 164.76%$ 164.757 millions
Amneal Pharmaceuticals Inc 159.59%$ 159.594 millions
Bio techne Corp143.31%$ 143.313 millions
Moderna Inc 139.13%$ 139.130 millions
Cellectar Biosciences inc 126.34%$ 126.341 millions
Inspiremd Inc 126.32%$ 126.316 millions
Cvrx inc113.92%$ 113.924 millions
Eli Lilly And Company113.82%$ 113.821 millions
Alpha Pro Tech Ltd 113.29%$ 113.287 millions
Docgo Inc 112.42%$ 112.423 millions
Castle Biosciences Inc 112.26%$ 112.255 millions
Beyond Air Inc 110.88%$ 110.883 millions
Editas Medicine Inc 109.46%$ 109.455 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com